本帖最后由 老马 于 2013-3-13 13:43 编辑
& B" X/ z* q8 f) _; V+ D! a
+ n1 A; ~2 m H健择(吉西他滨)+顺铂+阿瓦斯汀
( K4 A# S) D2 i7 q6 F L0 w Gemzar +Cisplatin + Avastin
) I3 u F* c/ J7 G% @) shttp://annonc.oxfordjournals.org/content/21/9/1804.full
- y! t% [+ k7 i% r, WOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) # E+ ~& t, b# a# S+ e! d- d
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
9 `* Z( n3 [: W3 ?3 Z. D1 ]/ UResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& ?/ ~- l6 D6 C! k G" j
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 829)
$ m# f& D8 |5 d0 ~+ B
华为网盘附件:- C( @/ V# t# M4 M$ X8 x9 }
【华为网盘】ava.JPG. M/ a: A/ _$ q/ e5 w. m/ r
|